LOC401317 Activators would imply a group of molecules that are capable of enhancing the activity of the protein product of the LOC401317 gene locus. These activators would have a specific affinity for the LOC401317 protein and would interact with it in a manner that increases its natural or baseline activity. The mechanisms by which these compounds would activate LOC401317 could be diverse, potentially involving direct binding to the protein to induce a conformational change that promotes activity, binding at allosteric sites to modulate function, or even affecting the levels of the protein by influencing gene expression, mRNA stability, or protein degradation pathways. Identification of such activators would likely involve high-throughput screening assays where various chemical compounds are tested for their ability to increase the activity of LOC401317, followed by a series of secondary assays to confirm and quantify the activation.
Diving deeper into the characterization of LOC401317 Activators, subsequent research would likely focus on the interaction dynamics between these molecules and the LOC401317 protein. Detailed biochemical studies would be conducted to assess the binding affinity and selectivity of these activators, utilizing techniques such as equilibrium dialysis, fluorescence polarization, or surface plasmon resonance (SPR). In conjunction with these, structural studies would be imperative to visualize how these activators interact with LOC401317, potentially employing methods like X-ray crystallography, NMR spectroscopy, or cryo-electron microscopy to obtain high-resolution structures of the protein both with and without the activator bound. These studies would reveal the precise binding sites and the structural changes upon activation, providing insights into the mechanism of action at a molecular level. Furthermore, computational approaches such as molecular docking and molecular dynamics simulations could predict interactions and suggest modifications to improve the efficacy of these activators. Through iterative cycles of design, synthesis, and testing, a comprehensive profile of the activators' effects on LOC401317 would be constructed. This would not only enhance the understanding of the protein's function but would also contribute to a broader appreciation of how small molecules can modulate protein activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a phosphodiesterase inhibitor, which increases cAMP levels, and may consequently enhance CREB5 expression through CRE-mediated gene transcription. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP and potentially upregulated CREB5 expression. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 binds to its receptors and can activate adenylate cyclase, leading to increased cAMP and possible induction of CREB5 expression. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
db-cAMP is a cAMP analog that can mimic the action of endogenous cAMP and may upregulate CREB5 expression. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine activates adenylyl cyclase via G protein-coupled receptors, increasing intracellular cAMP and potentially enhancing CREB5 expression. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine can activate adenylyl cyclase through its A2 receptors, increasing cAMP levels and possibly CREB5 expression. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline is another non-specific phosphodiesterase inhibitor that raises cAMP levels and may influence CREB5 expression. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine, similar to theophylline, inhibits phosphodiesterases leading to increased cAMP and potential upregulation of CREB5. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that can increase cAMP and thereby potentially induce CREB5 expression. | ||||||